MedTrace Logo

Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients

NCT00834262 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 339

Last updated 2016-10-31

No results posted yet for this study

Summary

This study is conducted in Asia. The aim of this observational study is to evaluate the safety profile and clinical effectiveness of using various pre-mixes of Biphasic Insulin Aspart under routine clinical practice conditions in Israel in Type 2 Diabetes patients.

Conditions

Interventions

DRUG

biphasic insulin aspart 30

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

DRUG

biphasic insulin aspart 50

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

DRUG

biphasic insulin aspart 70

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00834262 on ClinicalTrials.gov